SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2027diaDexus Announces Scientific Presentations at AACR Friday March 26, 8:02 am ET nigel bates-3/26/2004
2026>>Iconix Pledges Public Release of Genomic Biomarker Data By a GenomeWebtuck-3/24/2004
2025And just to pile on, you really have to read the full paper to understand the abkeokalani'nui-3/22/2004
2024Results in CCR2 knockout mice in different disease models are all over the placeBiomaven-3/22/2004
2023>> Let me get this straight ... These guys are saying that CCR2 expressionscaram(o)uche-3/22/2004
2022>>Experimental arthritis in CC chemokine receptor 2–null mice closely mimimicrocapfun-3/21/2004
2021Message 19921279keokalani'nui-3/16/2004
2020BJ, thanks for your detailed response. salessoftware salesperson-3/6/2004
2019I also listened to the Lehman Bros. presentation and would add the following comBiotech Jim-3/6/2004
2018BJ, what are your thoughts on incy's novel sheddase inhibitors for cancer software salesperson-3/4/2004
2017Guess I should stop waiting for $4. Argg.keokalani'nui-3/4/2004
20163/3/04 lehman brothers reverset provides coverage against m184v, which confers software salesperson-3/3/2004
2015A more recent study on NRTI resistance patterns that talks of both K65R & Q1tuck-2/17/2004
2014And from the FDA's HIV/AIDS website, this letter from Gilead: "Octobertuck-2/17/2004
2013These findings were presented at the 11th Annual Conference on Retroviruses and tuck-2/17/2004
2012One small additional anecdote from the CC: I didn't get all the details (anBiomaven-2/13/2004
2011It's CCR5 and it's early (PI done, but not PII not yet begun?). For a ftuck-2/13/2004
2010>>Reverset is likely ultimately going after patients looking for a friendltuck-2/13/2004
2009Premium is well on the low side. Clear move to wipe the old cv's off the boorkrw-2/12/2004
2008I was about to copy the convert p.r. when I saw your msg. You're right, the tom pope-2/12/2004
2007Thanks, sales, And this convert deal doesn't look too bad, either: >>tuck-2/12/2004
20062/12/04 Reverset conference call to view slides, go here: www.incyte.com/webcsoftware salesperson-2/12/2004
2005No doubt PFE's oral chemokine receptor entry inhibitor program (CCR4 or 5?) keokalani'nui-2/12/2004
2004tuck, The PGNX program is interesting, but they are only targeting a subgroup oBiomaven-2/12/2004
2003Competition . . . I'd be curious to know what folks think are the mosttuck-2/12/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News